The potential mechanism of primary resistance to icotinib in EGFR uncommon mutant advanced non-small cell lung cancer: a multi-center study.
The incidence of EGFR uncommon mutation (EGFRum) is relatively low and patients harboring EGFRum were considered to be resistant to the first generation TKIs. However, the mechanism of primary resistance is still unclear. The medical record of 98 patients who have never been treated by TKIs accepted icotinib treatment were collected and followed. The circulating tumor DNA(ctDNA) were detected and analyzed by next-generation sequencing(NGS) platform after progression from icotinib. The potential primary resistance mechanism of icotinib was explored. 21(21.4%) and 48(49%) patients developed primary and acquired resistance to icotinib, respectively. The median PFS time of primary resistance patients was 1.8 months (0.5-2.3, 95% CI=1.50-2.10). A total of 52.4% (11/21) patients carried S768I, 23.8% (5/21) L861Q, 14.3% (3/21) G719X, 14.3% (3/21) exon 20-ins mutations before treatment. About 23.8% (5/21) patients harbored the combined pattern mutations and 76.2% (16/21) patients harbored the single pattern mutations. The combined pattern with EGFR classical mutation(EGFRcm) had worse PFS than the combined with EGFRum and single pattern(P<0.05). There were 6(28.57%) patients acquired EGFR extracellular domain mutation, 5(23.81%) BCL2L11 loss (BIM deletion polymorphism), 3(14.29%) MET amplification, 1(4.76%) ERBB2 amplification, 1(4.76%) MYC amplification, 1(4.76%) PTEN mutation, 1(4.76%) PIK3CA mutation, and 3 (14.29%) unknown status. EGFR extracellular domain mutation, BCL2L11 loss, PI3K-AKT-mTOR signaling pathway (PTEN, PIK3CA mutations), MET amplification, ERBB2 amplification or MYC amplification might contribute to molecular mechanisms of primary resistance to icotinib in EGFR uncommon mutations NSCLC. Combined targeted therapy or chemotherapy should be considered in this population.